Compare FLL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | ZNTL |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 118.3M |
| IPO Year | 1993 | 2020 |
| Metric | FLL | ZNTL |
|---|---|---|
| Price | $2.88 | $1.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.00 | ★ $5.87 |
| AVG Volume (30 Days) | 160.2K | ★ 494.2K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $299,916,000.00 | $26,865,000.00 |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $2.25 | $1.01 |
| 52 Week High | $5.59 | $3.53 |
| Indicator | FLL | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 49.62 |
| Support Level | $2.61 | $1.34 |
| Resistance Level | $3.25 | $1.48 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 52.84 | 55.88 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.